Inoviq Ltd · ASX:IIQ
Inoviq — Bell Potter Healthcare Conference 2022
25 slides from Inoviq's conference presentation, Nov 10, 2022
Slide 1: Investor Presentation
Investor Presentation Bell Potter Healthcare Conference 10 November 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) based on Actual results, performance or achievements could be significantly different from those expressed information available to it as at the date of this presentation. This presentation contains general
Slide 3: INOVIQ at a glance
INOVIQ at a glance Developing next-generation exosome Proprietary technology platforms for Products in-market for exosome capture tools and precision diagnostics biomarker isolation and detection research & bladder cancer for cancer and other diseases $15b GLOBAL TAM Multi-product pipeline for detec
Slide 4: Key company metrics and strong funding position
Key company metrics and strong funding position $13.5m 92,018,702 $0.55 $50.61m Cash at bank1 Ordinary shares2 Share price2 Market capitalisation2 Share price performance A$607k 34.9% Ave monthly cash burn Top 20 holders2 4 | 1. Cash at 30 Sep 22 | 2. As at 9 Nov 2022.
Slide 5: Unmet need for earlier cancer detection
Unmet need for earlier cancer detection Unmet need 120% 5-year survival rates by stage at diagnosis1 • Unmet needs for non-invasive, accurate and reliable 99% 98%100% 100% 96% diagnostic tests for earlier cancer detection and monitoring 90% 93% • Earlier detection improves treatment options, patient
Slide 6: Global cancer diagnostics market
Global cancer diagnostics market Global cancer burden is 50.6m 4.9m prevalence prevalence 7.8m survivors, 19.3m new cases and 10.0m 1.1m incidence $3.3b $4.2b incidence 2.3m deaths pa1 PROSTATE CANCER BREAST CANCER 375k deaths deaths 689k Global cancer diagnostics market valued at US$250b2 380k prev
Slide 7: Broad development pipeline provides multiple shots on goal
Broad development pipeline provides multiple shots on goal ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT REGISTRATION hTERT1 Bladder Cancer ICC Adjunct to cytology In-market EXO-NET-RUO Exosome Capture Device Research tool In-market Exosome-OC2 (OCRF-7) Ovarian
Slide 8: SubB2M: Improves specificity in cancer detection and monitoring
SubB2M | Improves specificity in cancer detection and monitoring SubB2M detects the pan-cancer biomarker, Neu5Gc, found at elevated levels in multiple human cancers1 Applications for detection and monitoring of multiple cancers (breast, ovarian, prostate, pancreatic, melanoma, and others) INOVIQ is
Slide 9: SubB2M: SPR test for cancer risk assessment
SubB2M | SPR test for cancer risk assessment • POC data in case-control studies showed the SubB2M-based SPR test detected: o Ovarian Cancer at 100% sensitivity and 100% specificity across all stages (n = 69) 1,2 o Breast Cancer at 95% sensitivity and 100% specificity across all stages (n = 118) 1,2,
Slide 10: SubB2M: Immunoassays for cancer monitoring
SubB2M | Immunoassays for cancer monitoring • SubB2M-based immunoassay development, optimisation and analytical validation underway at ResearchDx1,2 • On-track to commence clinical testing by Dec-22 • SubB2M-based immunoassays detect Neu5Gc-decorated cancer antigens: o SubB2M/CA15.3 test for monitor
Slide 11: SubB2M: Development plan. Targeting LDT launch 2H CY2023
SubB2M | Development plan. Targeting LDT launch 2H CY2023 PROJECT PLAN CY2022 CY2023 Feasibility testing Assay development Retrospective clinical study 1 (diagnostic accuracy by cancer stage) Retrospective clinical study 2 (clinical performance for monitoring) Analytical validation Clinical validati
Slide 12: EXO-NET I Exosomes - like a message in a bottle
EXO-NET I Exosomes - like a “message in a bottle” • Exosomes are small extracellular vesicles (sEVs; 30-150nm) released from most cells, including cancer cells, into body fluids (plasma, saliva, urine, CSF) • Exosomes contain biomolecules (DNA, RNAs, proteins) and deliver these “messages” between ce
Slide 13: EXO-NET I Exosome isolation tools
EXO-NET I Exosome isolation tools • EXO-NET pan-exosome capture is a ‘research use only’ (RUO) product for isolation of exosomes from body fluids with speed, purity and yield advantages • Enables rapid, efficient and scalable isolation of exosomes • Suitable for biomarker discovery, research & devel
Slide 14: EXO-NET: Solution for EV Based Diagnostics
EXO-NET | Solution for EV Based Diagnostics • Fully automatable for high-throughput sample processing • Compatible with routine pathology laboratory workflows for downstream processing 96 samples/20 min Automated EXONET Automated RNA Liquid Biopsy Sample collection EV isolation isolation Digital PCR
Slide 15: EXO-NET I Efficient Isolation of plasma EV derived RNAs
EXO-NET I Efficient Isolation of plasma EV derived RNAs EXONET outperforms or is equivalent EXONET comparison to 4 commercial kits to 4 commercial EV isolation kits for 45.00 recovery of EV micro RNA (miRNA) and messenger (mRNA) as indicated by 40.00 lower CT values.1,2 Mean CT Value 35.00 30.00 “Th
Slide 16: EXO-NET in summary
EXO-NET in summary FAST Easy and convenient workflow with only 15 minutes EV capture SAMPLE Optimal solution for very low volume and rare samples from plasma, urine, VERSATILITY saliva HIGH YIELD High yield and capture of EVs from various biofluids Reduced co-isolation of contaminants and high enric
Slide 17: EXO-NET I Exosome-based diagnostics pipeline
EXO-NET I Exosome-based diagnostics pipeline Collaboration with UQ to develop world-first exosome-based ovarian cancer screening test1 AA OCRF-7 OCRF-7 BB CA-125 • EXO-NET technology used for fast and accurate 1.0 1.0 1.0 1.0 and scalable exosome isolation 0.8 0.8 0.8 0.8 predictive predictive Poste
Slide 18: Competitor comparison
Competitor comparison Promising early data compared to commercially available tests for breast and ovarian cancers Breast Cancer Detection Ovarian Cancer Detection 120.0% 120.0% 100.0% 100.0% 80.0% 80.0% 60.0% 60.0% 40.0% 40.0% 20.0% 20.0% 0.0% 0.0% S2M-SPR CA15.3 MMG S2M-SPR CA125 OVA1 ROMA Sens (I
Slide 19: LDT to IVD commercialisation path
LDT to IVD commercialisation path INOVIQ is focused on the LDT → IVD commercialization route to take products to market. Two main pathways: in the US: 1. Laboratory developed test (LDT) – 2 Commercialise as Lab Developed Tests (LDT) EARLY REVENUES & INITIAL MARKET ACCEPTANCE 1 3 development and vali
Slide 20: Expected achievements and catalysts
Expected achievements and catalysts 4Q CY2022 CY2023 ✓ Agreement with Nicoya to transfer, develop - SubB2M BC test results & evaluate SubB2M SPR test - SubB2M OC test results ✓ Canadian patent granted for BARD1 - Secure LDT laboratory partner - Commence SubB2M clinical studies for BC - SubB2M analyt
Slide 21: Investment summary
Investment summary Highly innovative Patented Strong Compelling Company Technology Pipeline Results Commercialised Significant growth Experienced Strong cash Products Potential Leadership Position 21 |
Slide 22: Contacts
Contacts INOVIQ Ltd Dr Leearne Hinch Chief Executive Officer 23 Normanby Road Notting Hill VIC 3168 e. lhinch@inoviq.com Australia m. +61 400 414 416 p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 22 |
Slide 23: Healthcare Experienced Board
Healthcare Experienced Board DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and international business Healthc
Slide 24: Management
Management DR LEEARNE HINCH DR GREG RICE PhD MARK EDWARDS Dr ROCCO IANNELLO Chief Executive Officer Chief Scientific Officer CFO & Company Secretary Business Development and Licensing Director Experienced biotechnology CEO with expertise in Internationally recognised scientist with over 30 years’ Hi
Slide 25: Strong patent portfolio
Strong patent portfolio Patent Family Title Granted Pending Expiry • Broad patent portfolio SubB2M protecting IIQ’s core PCT/AU2017/051230 (WO 2018/085888) Subtilase cytotoxin B subunit mutant AU, US BR, CA, CN, 2037 biomarker isolation and EP, IN, JP, KR, US (cont) detection technologies PCT/AU2022